DBV Technologies (NASDAQ:DBVT) Shares Up 3.1% – Should You Buy?

Shares of DBV Technologies S.A. (NASDAQ:DBVT) rose 3.1% on Monday . The stock traded as high as $19.90 and last traded at $19.77. Approximately 178,413 shares were traded during trading, a decline of 21% from the average daily volume of 226,419 shares. The stock had previously closed at $19.17.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of DBV Technologies in a report on Monday, December 22nd. HC Wainwright set a $40.00 price objective on shares of DBV Technologies in a research report on Thursday, December 18th. Zacks Research raised shares of DBV Technologies from a “strong sell” rating to a “hold” rating in a report on Monday, September 29th. Wall Street Zen upgraded shares of DBV Technologies from a “sell” rating to a “hold” rating in a research note on Friday, November 28th. Finally, Citigroup restated an “outperform” rating on shares of DBV Technologies in a research report on Wednesday, December 17th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, DBV Technologies has a consensus rating of “Moderate Buy” and a consensus target price of $35.38.

DBV Technologies Trading Down 0.4%

The stock has a market cap of $766.86 million, a PE ratio of -3.69 and a beta of -1.10. The business has a 50-day moving average price of $15.67 and a 200-day moving average price of $12.25.

Insider Transactions at DBV Technologies

In other news, major shareholder Bpifrance Epic sold 2,076,990 shares of DBV Technologies stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $4.85, for a total value of $10,073,401.50. Following the sale, the insider owned 8,595,472 shares in the company, valued at $41,688,039.20. This trade represents a 19.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.44% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of DBVT. Nan Fung Trinity HK Ltd. purchased a new stake in DBV Technologies during the 2nd quarter worth approximately $340,000. Vivo Capital LLC acquired a new position in DBV Technologies in the 2nd quarter valued at $9,659,000. MPM Bioimpact LLC purchased a new position in DBV Technologies in the 2nd quarter valued at $9,649,000. Adage Capital Partners GP L.L.C. purchased a new position in DBV Technologies in the 2nd quarter valued at $9,659,000. Finally, Octagon Capital Advisors LP acquired a new stake in DBV Technologies during the 2nd quarter worth $9,315,000. 71.74% of the stock is owned by hedge funds and other institutional investors.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.